As of 2025-07-10, the Intrinsic Value of Viking Therapeutics Inc (VKTX) is -5.71 USD. This VKTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 30.40 USD, the upside of Viking Therapeutics Inc is -118.78%.
Based on its market price of 30.40 USD and our intrinsic valuation, Viking Therapeutics Inc (VKTX) is overvalued by 118.78%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.71 - -5.71 | -5.71 | -118.78% |
| P/E | (20.03) - (27.61) | (24.69) | -181.2% |
| DDM - Stable | (7.57) - (27.21) | (17.39) | -157.2% |
| DDM - Multi | (0.19) - (0.53) | (0.28) | -100.9% |
| Market Cap (mil) | 3,414.22 |
| Beta | 1.31 |
| Outstanding shares (mil) | 112.31 |
| Enterprise Value (mil) | 3,376.28 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.17% |
| Cost of Debt | 5.00% |
| WACC | 7.42% |